entertainment -WSS

entertainment

author：knowledge 2025-10-01 23:02:34 - browse：536

Sammy Kimball for STAT

Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Gene therapy’s promise and the high cost of hope

focus

WSS

ER docs worry over extreme heat as a 'mass casualty event'

For BCIs, commercial hurdles may be bigger than scientific ones

Lung cancer screening guidelines updated for cigarette smokers

Gene therapy’s promise and the high cost of hope

Stem cell clinics for heart failure: buyer be wary

Live blog: Hearing on CRISPR

leisure time

entertainment

entertainment

Apple is now the first public company to be valued at $3 trillion

Inari Medical to buy amputation prevention company LimFlow

What does generative AI mean for health care? We asked experts

ProMED, early warning system on disease outbreaks, in peril

Medicare details structure of new drug price negotiation program

The drug industry sees a key ally in the Senate prevail

Psychedelics group wrestles with new pharma identity

DeepMind touts AlphaFold's new skills as protein folding AI models face off

The high cost of giving birth even with insurance

Attacks on the drug industry will lead to fewer breakthroughs

hotspot

What the cancer research community can learn from the Covid response

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Humans aren't the only ones with an imagination. Rats have it too

Microsoft strikes partnership with Duke Health to advance health AI

Dramatically reducing cancer deaths requires the PASTEUR Act

knowledge

knowledge

focus

explore